7th Aug 2015 05:14
LONDON (Alliance News) - GlaxoSmithKline PLC and Theravance Inc on Thursday announced the approval in Canada of BREO ELLIPTA for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease.
BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma.
BREO is administered once daily via the dry powder inhaler called ELLIPTA, which is also used across a range of other approved respiratory medicines in the GSK portfolio.
Asthma is a chronic lung disease that inflames and narrows the airways.1 Approximately 2.5 million people in Canada currently have asthma.
Copyright RTT News/dpa-AFX
Related Shares:
Glaxosmithkline